Prostate Cancer
Conditions
Brief summary
This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.
Interventions
OTHERIntermittent Fasting
Dietary intervention
Sponsors
State University of New York at Buffalo
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Longitudinal
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* In order to be eligible for participation in this trial, the subject must: * Be willing and able to provide written informed consent for the trial. * Be male at birth and least 18 years of age on day of signing informed consent. * Have measurable prostate cancer disease and be eligible for androgen deprivation therapy. * Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. * Demonstrate adequate organ function (all screening labs should be performed within 10 days of treatment initiation). * Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment. * Subjects must have a life expectancy of at least 6 months.
Exclusion criteria
* Has an ECOG performance of 2 or higher. * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the beginning of the treatment. * Has a known additional malignancy that is progressing or requires active treatment. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Has a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT/MRI imaging * Has any other medical intervention or condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives. * Is not willing and able to provide written informed consent for the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Enrollment rate | 3 years | Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy |
| Drop-out rate | 3 years | Feasibility of intermittent fasting (with the option of a plant-enriched diet) in prostate cancer patients receiving androgen deprivation therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients who achieve either partial or complete response by RECIST criteria on tumor imaging. | 3 years | Clinical efficacy of the combination of intermittent fasting with or without a plant-enriched diet plus androgen deprivation therapy |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. | 3 years | Safety, tolerability and reduction of common toxicities of the combination of intermittent fasting and the option of a plant-enriched diet intervention as compared to historical data. |
Countries
United States
Contacts
CONTACTRoberto Pili, MD
CONTACTKyle Pasquariello
Outcome results
None listed